February 1, 2018 / 12:13 PM / 7 months ago

BRIEF-PharmAbcine Enters in Collaboration With MSD

Feb 1 (Reuters) - Merck & Co Inc:

* PHARMABCINE ENTERS COLLABORATION WITH MSD FOCUSED ON CLINICAL EVALUATION OF TTAC-0001 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN RECURRENT GLIOBLASTOMA AND BREAST CANCER

* PHARMABCINE SAYS WILL CONDUCT INTERNATIONAL PHASE I/II STUDIES TO EVALUATE POTENTIAL CLINICAL SYNERGY OF COMBINING TTAC-0001 WITH KEYTRUDA

* PHARMABCINE INC SAYS HAS ENTERED INTO A COLLABORATIVE AGREEMENT WITH MSD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below